Inclusion Criteria:

- Adult over 18,

- WHO performance status ≤ 2,

- Hepatocellular carcinoma histologically or cytologically proven, or association of
liver tumor with chronic hepatopathy and AFP > 400 ng/ml, or tumorous hepatic
formation considered as hypervascularised by at least 2 methods of imaging in
cirrhotic patient, Non operable, non resectable, non transplantable, non accessible
to percutaneous treatment tumor,

- Measurable tumor, uni- or multinodular, taking up less than 50% of hepatic volume,

- Stage A to C of the BCLC classification (or stage 0 to 4 of the CLIP) with:

- No thrombosis of the portal vein, therapeutic escape or intolerance causing the
end of the treatment or contraindication to sorafenib

- If thrombosis of the portal vein, therapeutic escape to Lipiocis,

- Possibility of treatment by intra-arterial radiotherapy over a decision of a
Multidisciplinary Committee,

- Written informed consent

Exclusion Criteria:

- Patient with a stage ≥ 3 toxicity of the CTCAE version 4

- Stage D of the classification BCLC

- Acute impairment of hepatic functions (Child-Pugh B9 or C)

- Grade III Hepatocarcinoma of the Okuda classification

- Encephalopathy with troubles even moderated of cognitive functions

- Advanced chronic respiratory insufficiency

- Creatinine clearance < 55 ml/min, polynuclear neutrophils < 1500 G/L, platelets < 50
G/L, prothrombin < 40% (INR > 2,3)

- Contraindication to the intra-arterial administration

- Patients who can't be followed up for psychological or geographic reasons

- Patients dependant on another person for daily care

- Urinary incontinence

- Progressive cancer

- Pregnant or breastfeeding woman, or not using adequate effective contraception method